Davidson J R, Potts N, Richichi E, Krishnan R, Ford S M, Smith R, Wilson W H
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710.
J Clin Psychopharmacol. 1993 Dec;13(6):423-8.
Clonazepam and placebo were administered in a double-blind pilot study to 75 outpatients with social phobia. The mean maximum dose of clonazepam was 2.4 mg/day at endpoint (range, 0.5 to 3 mg). Treatment was continued for up to 10 weeks. The results of an intent-to-treat analysis indicated superior effects of clonazepam on most measures. Response rates for clonazepam and placebo were 78.3 and 20.0%. Drug effects were apparent on performance and generalized social anxiety, on fear and phobic avoidance, on interpersonal sensitivity, on fears of negative evaluation, and on disability measures. Significant differences were evident by week 1, 2, or 6, depending upon the rating scale used. Clonazepam was well tolerated in general, although unsteadiness and dizziness were more severe and persistent than was the case for placebo subjects.
在一项双盲试点研究中，对75名社交恐惧症门诊患者给予氯硝西泮和安慰剂。在研究终点时，氯硝西泮的平均最大剂量为2.4毫克/天（范围为0.5至3毫克）。治疗持续长达10周。意向性分析结果表明，氯硝西泮在大多数指标上效果更佳。氯硝西泮和安慰剂的有效率分别为78.3%和20.0%。药物对表现和广泛性社交焦虑、恐惧和恐惧回避、人际敏感性、对负面评价的恐惧以及残疾指标均有明显作用。根据所使用的评定量表，在第1周、第2周或第6周时，差异显著。总体而言，氯硝西泮耐受性良好，不过与服用安慰剂的受试者相比，不稳和头晕症状更为严重且持续时间更长。
